Last reviewed · How we verify
GW642444M
At a glance
| Generic name | GW642444M |
|---|---|
| Also known as | GW642444 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects (PHASE1)
- A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients (PHASE1)
- A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients (PHASE1)
- Safety, Blood Levels and Effects of GW642444 (PHASE1)
- Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects (PHASE1)
- A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment. (PHASE1)
- Phase I Study of GW642444M in Healthy Japanese Male Subjects (PHASE1)
- A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW642444M CI brief — competitive landscape report
- GW642444M updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI